Literature DB >> 9067916

Genetic linkage analysis of growth factor loci and end-stage renal disease in African Americans.

B I Freedman1, H Yu, B J Spray, S S Rich, C B Rothschild, D W Bowden.   

Abstract

Hypertension, diabetes mellitus and chronic glomerular diseases reportedly cause in excess of 80% of the incident cases of end-stage renal disease (ESRD) in the U.S. The factors that initiate progressive renal failure in patients with these disorders remain unknown. Several investigators have reported enhanced synthesis and activity of cytokines in the kidneys of patients with renal failure. The ensuing inflammation and fibrosis have been postulated to contribute to the development of progressive renal failure. There is also abundant evidence supporting the contribution of genetic factors in ESRD susceptibility based upon the strong familial clustering of ESRD, particularly in African Americans. Therefore, genetic linkage analysis may be useful to evaluate the role of candidate genes in several cytokine cascades that could contribute to the pathogenesis of chronic renal failure. We tested for genetic linkage between eight cytokine candidate genes and chronic renal failure in a collection of African American sibling pairs concordant for ESRD. Epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF) beta 1, TGF-beta 2 and TGF-beta 3, and tumor necrosis factor (TNF)-alpha and TNF-beta candidate genes were selected for analysis due to their putative roles in diabetic renal disease and chronic glomerulonephritis. The interleukin-1 receptor antagonist gene (IL1RN) was also genotyped due to its reported association with diabetic nephropathy. Non-parametric (genetic model independent) affected sib pair linkage analysis was used to evaluate evidence for linkage. In order to genotype TGF-beta 3, we identified four closely linked, previously unidentified, highly polymorphic microsatellite loci near the TGF-beta 3 gene. Linkage of ESRD and transforming growth factor beta 2 polymorphisms on human chromosome 1 approached significance for non-diabetic nephropathy (predominantly chronic glomerular disease, hypertensive nephrosclerosis and unknown etiology) (P = 0.08), but showed no linkage to diabetic nephropathy. The other candidate loci did not demonstrate linkage to ESRD in the total population or in the subgroups with diabetic or non-diabetic etiologies of ESRD. The IL1RN gene did not show significant evidence for linkage to ESRD; however, we did confirm an association between allele 2 of IL1RN and ESRD (as reported in diabetic nephropathy). Overall, these results suggest that these growth factor loci do not make major contributions to the pathogenesis of ESRD in African Americans.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067916     DOI: 10.1038/ki.1997.115

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  Evaluation of genetic association and expression reduction of TRPC1 in the development of diabetic nephropathy.

Authors:  Dongying Zhang; Barry I Freedman; Milan Flekac; Elisabete Santos; Pamela J Hicks; Donald W Bowden; Suad Efendic; Kerstin Brismar; Harvest F Gu
Journal:  Am J Nephrol       Date:  2008-09-19       Impact factor: 3.754

2.  Role of transforming growth factor-β2 in, and apossible transforming growth factor-β 2 gene polymorphism as a marker of, renal dysfunction in essential hypertension: A study in Turkish patients.

Authors:  Zerrin Bicik; Sevim Gönen; Talat Bahçebasi; Kadriye Reis; Turgay Arinsoy; Sükrü Sindel
Journal:  Curr Ther Res Clin Exp       Date:  2005-07

Review 3.  Genetics of diabetes complications.

Authors:  Donald W Bowden
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

4.  Rapid progression to end-stage renal disease in young hypertensive African Americans with proteinuria.

Authors:  C I Obialo; K Hewan-Lowe
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

5.  Linkage analysis of glomerular filtration rate in American Indians.

Authors:  Amy K Mottl; Suma Vupputuri; Shelley A Cole; Laura Almasy; Harald H H Göring; Vincent P Diego; Sandra Laston; Nora Franceschini; Nawar M Shara; Elisa T Lee; Lyle G Best; Richard R Fabsitz; Jean W MacCluer; Jason G Umans; Kari E North
Journal:  Kidney Int       Date:  2008-08-13       Impact factor: 10.612

6.  Interleukin-10 promoter polymorphism is associated with the predisposition to the development of IgA nephropathy and focal segmental glomerulosclerosis in Korea.

Authors:  Ho Jun Chin; Ki Young Na; Soo Jin Kim; Kook-Hwan Oh; Yon Su Kim; Chun Soo Lim; Suhnggwon Kim; Dong-Wan Chae
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

7.  Genetic analysis of diabetic nephropathy on chromosome 18 in African Americans: linkage analysis and dense SNP mapping.

Authors:  Caitrin W McDonough; Meredith A Bostrom; Lingyi Lu; Pamela J Hicks; Carl D Langefeld; Jasmin Divers; Josyf C Mychaleckyj; Barry I Freedman; Donald W Bowden
Journal:  Hum Genet       Date:  2009-12       Impact factor: 4.132

8.  Genetic contribution and associated pathophysiology in end-stage renal disease.

Authors:  Suraksha Agrawal; Ss Agarwal; Sita Naik
Journal:  Appl Clin Genet       Date:  2010-08-05

9.  Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension.

Authors:  Tang-Dong Liao; Xiao-Ping Yang; Yun-He Liu; Edward G Shesely; Maria A Cavasin; William A Kuziel; Patrick J Pagano; Oscar A Carretero
Journal:  Hypertension       Date:  2008-06-09       Impact factor: 10.190

10.  Exploration of the utility of ancestry informative markers for genetic association studies of African Americans with type 2 diabetes and end stage renal disease.

Authors:  Keith L Keene; Josyf C Mychaleckyj; Tennille S Leak; Shelly G Smith; Peter S Perlegas; Jasmin Divers; Carl D Langefeld; Barry I Freedman; Donald W Bowden; Michèle M Sale
Journal:  Hum Genet       Date:  2008-07-25       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.